MICROPORT (00853) rose more than 5%, with the stock up 5.19% to HK$1.42 by the time of writing, generating a turnover of HK$19.4691 million. The increase follows the recent release of Shanghai Microport Endovascular Medtech (Group) Co., Ltd.'s 2025 annual performance report. The subsidiary reported operating revenue of approximately RMB 1.351 billion, a year-on-year increase of 11.96%. Net profit attributable to owners of the parent company was approximately RMB 563 million, up 12.17% compared to the previous year. Basic earnings per share were RMB 4.65.
During the reporting period, the company's overseas sales revenue exceeded RMB 250 million, marking a growth of over 55% year-on-year. This segment now accounts for more than 18% of the company's total revenue. The company continues to advance collaborations with leading regional and global industry clients and is steadily progressing with market access and promotion efforts for its aortic and peripheral vascular intervention products in Europe, Latin America, Asia-Pacific, and other regions.
The company's product pipeline is robust, with development progressing steadily. The Aegis II abdominal aortic stent graft system has completed its registration dossier submission. The Hector multi-branch thoracic aortic stent graft system has entered the pre-market multi-center clinical trial stage in China and was included in the national innovative medical device "green channel" during the reporting period. This product has also achieved commercialization in the EU via a custom-made route, and an application for Breakthrough Device Designation has been submitted to the US FDA. The thoracoabdominal aortic stent graft system (custom) has obtained domestic filing approval. The iliac artery branch stent graft system is set to enter the clinical trial initiation phase.
Comments